Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag497 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Ankur Gupta-Wright und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: Drug Resistance, Bacterial, Anti-Bacterial Agents, Epidemiological Monitoring. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Department of Health and Social Care, Fleming Fund, UK National Institute for Health and Care Research.
Abstract (Originalsprache)
Antimicrobial resistance (AMR) is a major global health threat, with the greatest burden falling on low- and middle-income countries (LMICs) also challenged with limited surveillance capacity. The UK Government's Fleming Fund was established in 2015 to strengthen AMR surveillance across Africa and Asia through a One Health approach. This paper draws on program experience, country implementation evidence, and published literature to describe how the Fleming Fund operationalized AMR surveillance, assess its contribution to the quantity and quality of surveillance data, identify key implementation challenges, and consider implications for future global surveillance strategies. The Fleming Fund combined investments in laboratory infrastructure, workforce development, quality assurance, data systems, governance, and data use. Across supported countries, these investments enabled substantial growth in routine bacteriology and antimicrobial susceptibility testing, strengthened reference and surveillance laboratory capacity, increased participation in external quality assessment, and expanded reporting to the World Health Organization's Global Antimicrobial Resistance and Use Surveillance System. The program also supported complementary surveillance approaches, including antimicrobial use and consumption data and, in some settings, burden-of-disease and genomic surveillance. Progress, however, has been uneven and remains vulnerable to fragile infrastructure, procurement and supply chain bottlenecks, workforce turnover, fragmented data systems, weak clinical–laboratory interfaces, limited representativeness, and uncertain long-term financing. The Fleming Fund experience shows that strengthening AMR surveillance in LMICs is feasible, but requires sustained, system-wide investment. Future strategies should prioritize integration with clinical care, stronger digital and analytical capacity, broader diagnostic access, and domestic financing to ensure that high-quality AMR data are generated, shared, and translated into action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease, Imperial College London, London, United Kingdom.
- Department of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Infectious Diseases, Bristol NHS Foundation Trust, Bristol, United Kingdom.
- Itad Ltd, Brighton, United Kingdom.
- Federal Ministry of Livestock Development, Abuja, Nigeria.
- Department of Veterinary Public Health and Preventive Medicine, University of Ibadan, Ibadan, Nigeria.
ORCID-Profile: Ankur Gupta-Wright, Victoria Adetunji, Ben Amos, Brian Asare, Nicholas Feasey, Freddy Eric Kitutu, Rebecca Maudling, Victor Moses Musyoki, Manish Pathak, Tamalee Roberts, Lamiaa Shehata, Tim Shorten, Shawn Ting, Paul Turner
Förderung
- UK Department of Health and Social Care
- Fleming Fund
- UK National Institute for Health and Care Research
- NIHR Imperial Biomedical Research Centre
- NIHR HealthTech Research
- In Vitro Diagnostics
Zitieren
APA
Gupta-Wright, A., Adeleke, S. Y., Adetunji, V., Ahsan, Q., Amatya, R., Amos, B., Asare, B., Bangura, S. I. O., Buhler, C., Feasey, N., Gordon, N. C., Hopkins, H., Kitutu, F. E., Leslie, T., Lo, I., Lo, S., Majekodunmi, A., Maudling, R., Mudenda, N. B., …, & Worth, T. D. (2026). Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag497
Vancouver
Gupta-Wright A, Adeleke SY, Adetunji V, Ahsan Q, Amatya R, Amos B, et al. Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag497
BibTeX
@article{GuptaWright2026,
author = {Gupta-Wright, Ankur and Adeleke, Suliat Yetunde and Adetunji, Victoria and Ahsan, Qadeer and Amatya, Ritu and Amos, Ben and Asare, Brian and Bangura, Sorie I O and Buhler, Cyril and Feasey, Nicholas and Gordon, N Claire and Hopkins, Heidi and Kitutu, Freddy Eric and Leslie, Toby and Lo, Ibrahima and Lo, Seynabou and Majekodunmi, Ayodele and Maudling, Rebecca and Mudenda, Ntombi B and Musyoki, Victor Moses and Nanjebe, Deborah and Oakley, Tessa and Pathak, Manish and Roberts, Tamalee and Shehata, Lamiaa and Shorten, Tim and Siddiky, Nure Alam and Stelling, John and Taimoor, Muhammad and Thwe, May Soe and Ting, Shawn and Torumkuney, Didem and Turner, Paul and Wildfire, Jacob and Worth, Timothy David},
title = {Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag497}
}
EUVIMED